

## Press release

### Treatment of severe heart failure - AI

# FineHeart receives support from Europe with a grant of up to 750,000 euros

*Within the framework of the "New Aquitaine" ERDF-SSE (FEDER) program 2021-2027*

**Bordeaux, France, December 3, 2024 - FineHeart, a clinical-stage medtech developing innovative medical devices for cardiology,** today announced that it has received 750,000 euros in funding from the European ERDF/ESF (FEDER) program. This program supports the Regional Development Fund and European Social Fund "Investment for growth and employment in the Nouvelle Aquitaine Region".

This grant is awarded to FineHeart to support the *First in Human (FIH)*, European clinical trials of Flowmaker®, the world's first cardiac assistance device that does not involve a heart bypass, but is implanted directly in the left ventricle, and operates without a driveline. This ERDF/ESF funding covers the development of the FIH "Clinical Programmer".

**Arnaud Mascarell, CEO and co-founder of Fineheart,** comments: *"We are delighted by the renewed support of the Nouvelle-Aquitaine Region, which, as the managing authority for European programs, is once again placing its trust in us. As we simultaneously pursue the clinical and industrial development of FlowMaker®, we are proud of this recognition, which reinforces our commitment. Contributing to the region's economic growth by developing cutting-edge, globally competitive know-how is a source of great pride for us."*

#### **About the ERDF program**

The European Regional Development Fund (ERDF) is part of the EU's economic, social and territorial cohesion policy. Its purpose is to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions. In France, for the period 2021-2027, the ERDF represents 8.4 billion euros dedicated to the "investment for growth and employment" objective, with a view to consolidating the labor market and regional economies.

#### **About the FlowMaker®**

**About FlowMaker®** is the first implantable cardiac output accelerator, designed by French electrophysiologists and rhythmologists. Fully intraventricular, it provides physiological support synchronized with the natural heart contractions. It respects natural blood flow and does not require aortic bypass, unlike other devices. It is the first miniaturized device – only 10 cm – that adapts to patients' needs like a pacemaker, allowing targeted treatment based on the severity and progression of the disease. Completely implanted in the patient's body, it has no external power cables as it is recharged via a transcutaneous energy transfer (TET) system, thereby avoiding any risk of infection and significantly improving patients' quality of life. The device is implanted through a minimally invasive procedure on a beating heart, with an average duration of 90 minutes. Thanks to its unique features, FlowMaker® represents an effective and highly promising therapeutic alternative for patients suffering from advanced heart failure who cannot benefit from current therapeutic solutions.

## About FineHeart - [FineHeart](#)

FineHeart is a Bordeaux-based medical device company at the clinical stage. Its innovative product, FlowMaker®, could treat 200,000 patients with severe heart failure every year. FineHeart is initially targeting the 50,000 most severe patients eligible for cardiac assistance, but not treated by current LVADs. This first potential market is estimated at over US\$5 billion.

FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stéphane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families. The first two patients have been implanted successfully as part of the European FIH (First In Human) trials. Further European cardiology centers are expected to join the trials shortly, including France.

FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi, M Capital, NACO, UI Investment, Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions.

## Contact

**Europe  
Media Relations**  
Annie-Florence Loyer  
afloyer@newcap.fr  
+33 (0) 6 88 20 3559

**FineHeart Communication**  
James Palmer  
[james.palmer@fine-  
heart.com](mailto:james.palmer@fine-heart.com)  
+33 (0) 7 60 92 77 72

**Helinnov - Consulting  
in financial management**  
Hélène Cima  
[helene.cima@helinnov.fr](mailto:helene.cima@helinnov.fr)  
+33 (0) 6 99 28 40 80